Skip to Main Content

Paper Details

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.
Cancer Discov
238
2020
AML, AML subclones, Acute Myeloid Leukemia, BCL2, MCL1, Monocytic Subclones, Patients, Venetoclax, acute myeloid leukemia, azacitidine, monocytic, monocytic AML, monocytic AML cells, monocytic subpopulations, patients, resistant monocytic AML, venetoclax
Author NameAffiliation
Shanshan PeiUniversity of Colorado School of Medicine
Daniel A PollyeaUniversity of Colorado School of Medicine
Brett M StevensUniversity of Colorado School of Medicine
Mohammad MinhajuddinUniversity of Colorado School of Medicine
James C CostelloUniversity of Colorado Anschutz Medical Campus
Maria AmayaUniversity of Colorado School of Medicine
Anagha InguvaUniversity of Colorado School of Medicine
Amanda WintersUniversity of Colorado School of Medicine
Haobin YeUniversity of Colorado School of Medicine
Anna KrugUniversity of Colorado School of Medicine
Courtney L JonesUniversity of Colorado School of Medicine
Biniam AdaneUniversity of Colorado School of Medicine
Diana AbbottCenter for Innovative Design and Analysis, Colorado School of Public Health
Travis NemkovUniversity of Colorado Denver
Travis NemkovUniversity of Colorado Denver
Angelo D'AlessandroUniversity of Colorado School of Medicine
Angelo D'AlessandroUniversity of Colorado Denver
Angelo D'AlessandroUniversity of Colorado School of Medicine
Angelo D'AlessandroUniversity of Colorado Denver
Clayton A SmithUniversity of Colorado School of Medicine
Veronica Clavijo JordanUniversity of Colorado School of Medicine
Veronica Clavijo JordanUniversity of Colorado School of Medicine
  • 1 - 22

Datasets